Search Medical Condition
Please enter condition
Please choose location

Montegnee, Belgium Clinical Trials

A listing of Montegnee, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (109) clinical trials

Safety Pharmacokinetics Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 3) as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV). This trial will be the first trial of tolvaptan in children and adolescents with ADPKD. ...

Phase

0.0 miles

Learn More »

Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

OBJECTIVES: Primary - Determine survival rates (event-free survival and overall survival [OS]) and the pattern of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery. - Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response ...

Phase

0.0 miles

Learn More »

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

This is a Phase 3 randomized, placebo-controlled, double-blind, multi-center trial stratified by donor age and by region to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from DBD donors who were at least 45 years of age.

Phase

2.05 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

2.25 miles

Learn More »

Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

Methodology: - A 5-year, multicentre, prospective, randomized, open-label, controlled study - Group 1: Simulect + cyclosporine + Myfortic + steroid stop at 3 months - Group 2: Simulect + cyclosporine (decrease dose in one week at month 3 and replace by everolimus) + Myfortic + steroid maintenance. - In both ...

Phase

2.25 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...

Phase

2.25 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

2.25 miles

Learn More »

Study Of Diabetic Nephropathy With Atrasentan

The study objective is to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine or the onset of end stage renal disease (ESRD) in subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose (MTLDD) of a ...

Phase

2.25 miles

Learn More »

Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study

Eligibility criteria: - 18 to 85 years. - Evidence of myocardial ischemia without raised troponin (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study). - The patient has a planned intervention of up to two de novo lesions in different epicardial vessels - Lesion(s) must have ...

Phase

2.25 miles

Learn More »

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Device-detected sub-clinical atrial fibrillation (SCAF) is a new disorder that has been recognized since the availability of implantable devices capable of long term continuous heart rhythm monitoring. It is characterized by one or more runs of rapid atrial arrhythmia detected by the device without symptoms and without any clinical atrial ...

Phase

2.25 miles

Learn More »